Business Context and Reporting Period
Company: Aquestive Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 26, 2020 (Event Date: June 29, 2020)
Business Overview: The Company is an emerging growth company developing drug delivery technologies, specifically its proprietary PharmFilm® technologies.
Key Financial Metrics
This filing is a current report regarding a regulatory milestone and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material event reported is the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA). This submission is for pharmacokinetic (PK) clinical trials of the drug candidate AQST-108.
Guidance, Outlook, and Management Commentary
- Drug Candidate: AQST-108 is described as a "first of its kind" oral sublingual film formulation.
- Active Ingredient: Systemic epinephrine.
- Indication: Treatment of anaphylaxis.
- Technology: Utilizes the Company's proprietary PharmFilm® technologies.
- Regulatory Status: IND application submitted to the FDA as of June 29, 2020.
Investor Verification Checklist
- Confirm the FDA's acceptance of the IND application for AQST-108.
- Review the attached press release (Exhibit 99.1) for specific trial design details.
- Monitor subsequent filings for the commencement of the pharmacokinetic (PK) clinical trials.
- Verify the Company's cash position in separate periodic reports (10-Q/10-K) to assess runway for clinical development.